Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Kicks Off Commissionership With Pledge To Counter Misinformation

Executive Summary

New FDA commissioner commitment to counter misinformation also appears to include pledge to ensure agency is driven by science-based decisions, not politics.

You may also be interested in...



A Little Help From His Friends: Califf Requests Patients Help US FDA Fight Misinformation

The idea seems to stem from thinking that human interaction is the best way to combat rumors and false statements.

US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’

Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.

US FDA’s Califf Says Publishing Complete Response Letters Could Help Fight Misinformation

But the commissioner also said proponents of releasing CRs may be making too much of the idea, because there are few CRs actually issued.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel